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Solid tumors are comprised of a surprisingly heterogeneouscollection of cells. As discussed in an introductory talk by
Dr. Rudin, recent studies focused on a wide diversity of
malignancies have begun to define phenotypically distinct
subsets of cancer cells that differ in terms of both clonogenic
potential in vitro and tumorigenic potential in vivo. These
studies have been interpreted by many as supporting the
cancer stem cell hypothesis.1 In brief, this hypothesis holds
that a small subpopulation of cancer cells within a tumor
retain the unique proliferative and differentiative capacity to
regenerate tumors. In contrast, the majority of cells within
tumors has limited replicative potential and may represent
terminally differentiated progeny of the cancer stem cells. An
increasingly broad and consistent body of evidence, from
both hematologic malignancies and solid tumors, supports
that separable phenotypically distinct populations of cancer
cells have radically different regenerative capacities. Even
very small numbers of purified populations of high-tumori-
genic capacity can be successfully transplanted, resulting in
tumors consistently recapitulating the full heterogeneity of
cell morphologies present in the tumor of origin.1
Several recent articles have sought to define character-
istics of putative stem cells for human lung cancer. Ho et al.2
demonstrated that bulk tumor cell sorting from non-small cell
lung cancer (NSCLC) cells lines by flow cytometry can be
used to isolate a subset of cells markedly enriched for tumori-
genic potential in vivo. Eramo et al.3 demonstrated, across all
major lung cancer histologies, that a subset of tumor cells
expressing elevated CD133 (a known marker of tumor progen-
itor cells in glioblastoma) is highly tumorigenic and recapitu-
lates the full diversity of CD133-high and low cells in
recipient animals. Most recently, Jiang et al.4 used a series of
primary xenograft small cell lung cancer to demonstrate that
the transcription factor ASCL1, implicated in multiple em-
bryonic developmental pathways, is markedly upregulated in
the CD133 progenitor cell compartment. ASCL1 was found
to be a transcriptional regulator of CD133 and suppression of
ASCL1 by shRNA markedly inhibited clonogenic potential.
Taken together, these recent articles strongly support the
existence of a subpopulation within human lung cancers
characterized by markedly elevated tumorigenic capacity.
SUMMARY OF RESEARCH PRESENTATIONS
The Hedgehog Signaling Pathway: A Cancer
Stem Cell Target
Several lines of evidence suggest that the Hedgehog
signaling pathway is dysregulated in cancer and plays a role
in cancer stem cell survival.5 Hedgehog pathway activation
occurs both by mutation in rare tumors and perhaps more
broadly by a paracrine mechanism involving cancer cells and
surrounding stromal cells, in tumors including small cell lung
cancer.6 Talks presented by Dr. Rudin, Dr. Weiss, and Dr.
Alland focused on three inhibitors of the Hedgehog pathway
in early clinical development.
Several orally bioavailable highly selective Hedgehog
pathway inhibitors are now in early-phase clinical develop-
ment in patients with advanced solid tumors. The first of
these to reach the clinic, GDC-0449, has been reported to
have potent antitumor activity in patients with advanced or
metastatic basal cell carcinoma in the initial phase I study.7 A
recommended phase II dose of 150 mg daily has been defined,
and multiple phase II studies are currently in progress or
planned. Two other inhibitors, IPI-926 and XL139 (BMS-
33923), are now in similar phase I dose-escalation studies in
patients with advanced solid tumors. One of these, IPI-926,
inhibits tumor transplantation and delays tumor recurrence
after cytotoxic chemotherapy in a primary xenograft model of
small cell lung cancer.8
Cyclooxygenase-2: A Regulator of Embryonic
Signaling Pathways in Cancer
Drs. Dubinett and von Roemeling discussed inhibitors
of cyclooxygenase 2 (COX-2) and PPAR, respectively, key
components of arachidonic acid metabolism pathways impli-
cated in carcinogenesis, invasion, and metastasis, and, in
emerging data, cancer stem cell biology.9 Prostaglandin E2
(PGE2) was recently found to influence expression of several
key regulators of embryonic stem cell development including
Snail, Zeb1, and Slug.10 Preliminary unpublished studies by
Tonya Walser et al., presented at the meeting, suggest that
exogenous Snail expression in nontransformed human bron-
chial epithelial cells induces expression of a number of putative
markers of tumor stem cells, including CD44, ABCG1, ALDH,
Notch, and Wnt pathway members. Taken together, these
observations suggest that COX-2 inhibition, by suppressing
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PGE2 levels, may selectively inhibit expression of genes
implicated in cancer stem cell survival.
Recent and ongoing studies of COX-2 inhibitors in lung
cancer provide insight into future clinical development.
Reckamp et al.11 reported a clinical study of celecoxib with
erlotinib, defining an optimal biologic dose for suppression of
PGE2 based on urinary PGE-M levels. This prompted an
ongoing biomarker-intensive study of erlotinib with or with-
out celecoxib in NSCLC, with evaluation of markers includ-
ing E-cadherin, Zeb1, and Snail. Dr. Edelman recently pre-
sented a study in advanced NSCLC suggesting that celecoxib
enhances chemotherapeutic efficacy specifically in cancers
demonstrating upregulated COX-2 expression.12 The recently
initiated CALGB 30801 study is designed to confirm this
result and to explore multiple putative correlative biomarkers.
Newer COX-2 inhibitors, including apricoxib, are also being
actively studied, alone and in combination with standard
second-line therapies including erlotinib, docetaxel, and pem-
etrexed in recurrent NSCLC.
Additional factors activated by arachidonic acid path-
ways include PPAR, overexpressed in many cancer types,
and implicated in cancer cell survival. Selective inhibition of
PPAR has been associated with terminal differentiation, cell
cycle arrest, and apoptotic induction.13 An orally bioavailable
selective inhibitor of PPAR, CS-7017, has recently com-
pleted phase I testing, and a phase II study of this agent in
advanced NSCLC is ongoing.
Targeting Apoptotic Resistance in Cancer Stem
Cells
One of the consistent features ascribed to cancer stem
cells across multiple tumor types is upregulated apoptotic
resistance, leading to ineffective killing by standard cytotox-
ics. As discussed by Dr. Minna, the inhibitor of apoptosis
proteins represents particularly attractive targets upregulated
in a wide variety of cancers including lung cancer. The
inhibitor of apoptosis proteins is held in check by a mito-
chondrial factor, SMAC.
Highly potent synthetic SMAC mimetics, such as JP1201,
have recently been developed and have demonstrated antitu-
mor activity in late phase preclinical testing.14 In preliminary
studies of Rachel Greer et al., JP1201 demonstrates single
agent activity in NSCLC xenografts and remarkable synergy
across multiple NSCLC cell lines with cytotoxics including
anthracyclines, taxanes, vinca alkaloids, and gemcitabine.
Clinical translation of these findings using this or related
SMAC inhibitors will be of significant interest.
Targeting the Long-Term Replicative Potential
of Cancer Stem Cells: Telomerase Inhibition
A hallmark of stem cells in general, and of cancer
progenitor populations in particular, is activation of telomer-
ase.15 Dr. Shay discussed development and early-phase clin-
ical testing of highly selective and potent inhibitors of telom-
erase. GRN163L is a competitive telomerase RNA template
antagonist, displacing the hTERC RNA and blocking telom-
erase function.16 In preclinical models of NSCLC, GRN163L
specifically blocks establishment of metastatic tumors in the
lung.17 In addition, treatment of established xenograft tumors
with a combination of cisplatin and GRN163L, but not cisplatin
alone, leads to durable complete responses, again supporting
a selective effect on tumorigenic capacity. Multiple phase I
studies of GRN163L are ongoing, including single agent
phase I dose-escalation studies in advanced solid tumor
patients and in hematologic malignancies. A phase I combi-
nation study limited to breast cancer, combining GRN163L
with paclitaxel and bevacizumab, has also launched.
Ras and Raf: Targeting a Central Pathway in
Lung Carcinogenesis
Drs. Reily and Johnston presented updates on novel in-
hibitors of K-Ras and Raf, respectively. Multiple murine models
of lung carcinogenesis, including models developed in the lab-
oratories of Tyler Jacks and of Harold Varmus, implicate K-Ras
as a gatekeeper mutation in airway epithelial transformation and
lung adenocarcinoma tumorigenesis. The Raf family of proteins
are primary downstream targets activated by K-Ras.
K-Ras itself has been considered a nearly undruggable
target. Salirasib is a novel small molecule that indirectly
inhibits K-Ras activity by displacing K-Ras from the inner
cytoplasmic membrane. A phase II study of salirasib in
NSCLC, restricted to either previously untreated smokers
(15 pack-years) or patients with KRAS mutant tumors, has
completed accrual. Although no objective responses were
seen, three of 12 evaluable patients with KRAS mutations
experienced prolonged stable disease (5–15 months).
XL281 is a selective inhibitor of Raf proteins and
shows preclinical activity in tumor models with mutant and
wild-type B-Raf, C-Raf, and activated K-Ras. A phase I study
has been completed, defining dose-limiting toxicities of nau-
sea, vomiting, diarrhea, and fatigue. Clinical on-target bio-
logic activity, based on MEK activation status, was docu-
mented. One partial response was observed, and again several
patients had prolonged stable disease.
Retinoids: Distinct Lung Carcinogenesis
Pathways in Smokers and Never Smokers
Multiple retinoids have been explored as differentiating
agents and potential chemopreventive agents in patients at
high risk of upper aerodigestive cancers. Dr. Lippman re-
viewed studies of particular relevance to lung cancer, focus-
ing on the interaction between retinoid therapy and active
tobacco use. A phase III study of 1166 patients with resected
stage I NSCLC randomized to the retinoid isotretinoin versus
placebo for 3 years showed no overall benefit, but subset
analyses suggested harm in current smokers and benefit in
never smokers.18 Updated unpublished analysis of mortality
from this study confirms a strong interaction between smok-
ing status and isotretinoin effect. These data are consistent
with other large chemoprevention and adjuvant studies dem-
onstrating negative smoking status–drug interactions, leading
to excess mortality in treated smokers.19,20
FUTURE DIRECTIONS
Recent data from multiple investigators have demon-
strated that specific tumor subsets have differential capacity
for tumor regeneration. Subsets with high-tumorigenic capac-
ity from multiple cancer types share certain key characteris-
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tics including relative apoptotic resistance and upregulation
of embryonic signaling pathways. Some cell surface markers
seem to be selectively expressed in tumor progenitor cell
populations across cancer types. A series of recent studies
have defined a cell population with high-tumorigenic capacity
in human lung cancers and primary xenograft models.
Several classes of therapeutic agents in late preclinical and
early-phase clinical development have potential to target key
survival pathways in these progenitor cells implicated in tumor
recurrence and progression. Results from these ongoing studies,
especially results of combination studies with cytotoxic chemo-
therapy, may reshape future directions of clinical research in
lung cancer.
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